SNDX SYNDAX PHARMACEUTICALS

Syndax Announces Participation in June Investor Conferences

Syndax Announces Participation in June Investor Conferences

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

  • Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.
  • Goldman Sachs 46th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 11, 2025, at 2:00 p.m. ET.

A live webcast of the fireside chats will be available in the Investor section of the Company's website at , where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on and .

Syndax Contacts

Sharon Klahre

Syndax Pharmaceuticals, Inc.



Tel 781.684.9827

SNDX-G



EN
29/05/2025

Underlying

SNDXSYNDAX PHARMACEUTICALS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SYNDAX PHARMACEUTICALS

 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Announces Participation in June Investor Conferences

Syndax Announces Participation in June Investor Conferences NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.Goldman Sachs 46th Annual Global Healthcare Conference with a fireside cha...

May 29, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
NCR NCR CORPORATION
TRS TriMas Corporat... ... (+55)

InsiderInsights Weekly Report: May 24, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

NCR NCR CORPORATION
TRS TRIMAS CORPORATION
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
MMLP MARTIN MIDSTREAM PARTNERS L.P.
JRVR JAMES RIVER GROUP HOLDINGS LTD
GLP GLOBAL PARTNERS LP
PATK PATRICK INDUSTRIES INC.
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
ELY CALLAWAY GOLF COMPANY
FLWS 1-800-FLOWERS.COM CL A
GBLI GLOBAL INDEMNITY PLC
SNDX SYNDAX PHARMACEUTICALS
HAIN THE HAIN CELESTIAL GROUP
NHF INC.
BRT NEXPOINT CREDIT STRATEGIES FUN
OCSL BRT APARTMENTS
MPB OAKTREE SPECIALTY LENDING CORPORATION
FGBI MID PENN BANCORP INC.
MIDD FIRST GUARANTY BANCSHARES
ENR THE MIDDLEBY CORPORATION
AVTR EDGEWELL PERSONAL CARE COMPANY
ZYME AVANTOR
VLA INC.
ONEW ZYMEWORKS INC.
ADV ARBOR METALS
DLHC ONEWATER MARINE
CVRX ADVANTAGE SOLUTIONS INC (A)
PFBX DALEIGH HOLDINGS CORP
TCRX CVRX
STGW INC.
OPAL PEOPLES FINANCIAL CORP. (MISSISSIPPI)
PRME FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
STRW STAGWELL INC
PHIN OPAL FUELS INC
SRBK PRIME MEDICINE INC
SDHC STRAWBERRY FIELDS REIT INC.
FIP PHINIA INC
SUNS SR BANCORP INC
EVM SMITH DOUGLAS HOMES CORP
TXO FTAI INFRASTRUCTURE INC
GF SUNRISE REALTY TRUST
FG EATON VANCE INSD CALIF MUN BD FD
GREE MORNINGSTAR PARTNERS
HCWB L.P.
IAE THE NEW GERMANY FUND
FINS INC.
F AND G ANNUITIES AND LIFE
INC.
GREENIDGE GENERATION HLDGS INC
HCW BIOLOGICS INC
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
05/26/25 May 26, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
NCR NCR CORPORATION
TTSH Tile Shop Holdi... ... (+34)

InsiderInsights.com Daily Ratings Report: May 19, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

NCR NCR CORPORATION
TTSH TILE SHOP HOLDINGS INC.
PLUG PLUG POWER INC.
MAIN MAIN STREET CAPITAL CORPORATION
PATK PATRICK INDUSTRIES INC.
ELY CALLAWAY GOLF COMPANY
UEIC UNIVERSAL ELECTRONICS INC.
UIHC UNITED INSURANCE HOLDINGS CORP.
FLWS 1-800-FLOWERS.COM CL A
SNDX SYNDAX PHARMACEUTICALS
NNBR NN
OCSL INC.
MPB OAKTREE SPECIALTY LENDING CORPORATION
ENR MID PENN BANCORP INC.
ZYME EDGEWELL PERSONAL CARE COMPANY
ARQT ZYMEWORKS INC.
HQL ARCUTIS BIOTHERAPEUTICS
ADV INC.
CVRX TEKLA LIFE SCIENCES INVESTORS
SRPT ADVANTAGE SOLUTIONS INC (A)
DMA CVRX
SUNS INC.
EVM SAREPTA THERAPEUTICS
TXO INC.
GF DESTRA MULTI ALTERNATIVE FUND
FG SUNRISE REALTY TRUST
IAE EATON VANCE INSD CALIF MUN BD FD
MORNINGSTAR PARTNERS
L.P.
THE NEW GERMANY FUND
INC.
F AND G ANNUITIES AND LIFE
INC.
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
05/20/25 May 20, 2025 1 EN
Free Trial
SNDX SYNDAX PHARMACE...

Syndax Pharmaceuticals Inc: 4 directors

Four Directors at Syndax Pharmaceuticals Inc bought 29,765 shares at between 8.990USD and 9.112USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...

SNDX SYNDAX PHARMACEUTICALS
05/19/25 May 19, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (...

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) – Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with chronic GVHD in the AGAVE-201 trial – NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovat...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch